RU2021113126A - Средства для лечения инфекции вируса гепатита в (hbv) и их применение - Google Patents
Средства для лечения инфекции вируса гепатита в (hbv) и их применение Download PDFInfo
- Publication number
- RU2021113126A RU2021113126A RU2021113126A RU2021113126A RU2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A RU 2021113126 A RU2021113126 A RU 2021113126A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- seq
- nucleic acid
- effector
- shmir
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims 11
- 208000015181 infectious disease Diseases 0.000 title claims 8
- 239000003814 drug Substances 0.000 title claims 3
- 229940079593 drug Drugs 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 claims 56
- 150000007523 nucleic acids Chemical class 0.000 claims 56
- 102000039446 nucleic acids Human genes 0.000 claims 56
- 239000012636 effector Substances 0.000 claims 39
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 32
- 230000000295 complement effect Effects 0.000 claims 25
- 239000013604 expression vector Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 12
- 239000002679 microRNA Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- 108091027967 Small hairpin RNA Proteins 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108020005065 3' Flanking Region Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 229960001997 adefovir Drugs 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- 229960000980 entecavir Drugs 0.000 claims 2
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229960001627 lamivudine Drugs 0.000 claims 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 229960004556 tenofovir Drugs 0.000 claims 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108020005029 5' Flanking Region Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332245P | 2016-05-05 | 2016-05-05 | |
| US62/332,245 | 2016-05-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142797A Division RU2748806C2 (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021113126A true RU2021113126A (ru) | 2021-08-20 |
Family
ID=60202535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021113126A RU2021113126A (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
| RU2018142797A RU2748806C2 (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142797A RU2748806C2 (ru) | 2016-05-05 | 2017-05-05 | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535851B2 (enExample) |
| EP (1) | EP3452595A4 (enExample) |
| JP (1) | JP2019514401A (enExample) |
| KR (1) | KR102358280B1 (enExample) |
| CN (1) | CN109415733A (enExample) |
| AU (2) | AU2017260580B2 (enExample) |
| CA (1) | CA3023185A1 (enExample) |
| PH (1) | PH12018502320A1 (enExample) |
| RU (2) | RU2021113126A (enExample) |
| SG (1) | SG11201809753YA (enExample) |
| WO (1) | WO2017190197A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023185A1 (en) * | 2016-05-05 | 2017-11-09 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
| CN113038955B (zh) * | 2018-11-16 | 2025-03-18 | 公益财团法人东京都医学总合研究所 | 用于抑制乙型肝炎病毒复制的组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| RU2217161C2 (ru) * | 1997-08-26 | 2003-11-27 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) | Способ лечения вирусного гепатита |
| ES2606290T3 (es) * | 2001-07-12 | 2017-03-23 | University Of Massachusetts | Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico |
| CN1257284C (zh) * | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US8575327B2 (en) * | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| EP2316942B1 (en) | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| WO2008147430A2 (en) * | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| WO2010140862A2 (ko) * | 2009-06-05 | 2010-12-09 | Seol Dai-Wu | 단일 또는 멀티 표적 유전자를 억제하는 멀티-시스트로닉 ｓｈＲＮＡ 발현 카세트 |
| US20130267429A1 (en) * | 2009-12-21 | 2013-10-10 | Lawrence Livermore National Security, Llc | Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes |
| KR101903778B1 (ko) | 2010-10-28 | 2018-10-04 | 베니텍 바이오파마 리미티드 | Hbv 치료 |
| TW202244278A (zh) * | 2011-06-30 | 2022-11-16 | 美商艾羅海德製藥公司 | 用於抑制ｂ型肝炎病毒基因表現之組合物及方法 |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| SMT202200337T1 (it) * | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| WO2014117050A2 (en) * | 2013-01-26 | 2014-07-31 | Mirimus, Inc. | Modified mirna as a scaffold for shrna |
| CN103088026A (zh) | 2013-02-01 | 2013-05-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 抗乙型肝炎病毒人工miRNA及其组合 |
| PL243776B1 (pl) * | 2013-09-02 | 2023-10-09 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Cząsteczka kwasu nukleinowego, kaseta ekspresyjna, wektor ekspresyjny, komórka eukariotycznego gospodarza i zastosowanie cząsteczki kwasu nukleinowego w terapii chorób wywoływanych ekspansją trójnukleotydowych powtórzeń typu CAG |
| KR20170141257A (ko) * | 2015-05-06 | 2017-12-22 | 베니텍 바이오파마 리미티드 | B형 간염 바이러스 (hbv) 감염의 치료를 위한 시약 및 이의 용도 |
| CA3023185A1 (en) * | 2016-05-05 | 2017-11-09 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
-
2017
- 2017-05-05 CA CA3023185A patent/CA3023185A1/en active Pending
- 2017-05-05 SG SG11201809753YA patent/SG11201809753YA/en unknown
- 2017-05-05 AU AU2017260580A patent/AU2017260580B2/en not_active Ceased
- 2017-05-05 RU RU2021113126A patent/RU2021113126A/ru unknown
- 2017-05-05 JP JP2018557875A patent/JP2019514401A/ja active Pending
- 2017-05-05 RU RU2018142797A patent/RU2748806C2/ru active
- 2017-05-05 CN CN201780040430.8A patent/CN109415733A/zh active Pending
- 2017-05-05 EP EP17792296.0A patent/EP3452595A4/en not_active Withdrawn
- 2017-05-05 US US16/098,759 patent/US11535851B2/en active Active
- 2017-05-05 KR KR1020187035341A patent/KR102358280B1/ko not_active Expired - Fee Related
- 2017-05-05 WO PCT/AU2017/050413 patent/WO2017190197A1/en not_active Ceased
-
2018
- 2018-11-05 PH PH12018502320A patent/PH12018502320A1/en unknown
-
2022
- 2022-09-27 AU AU2022241489A patent/AU2022241489A1/en not_active Abandoned
- 2022-11-18 US US18/056,929 patent/US20230093951A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3452595A4 (en) | 2020-02-19 |
| KR102358280B1 (ko) | 2022-02-07 |
| US11535851B2 (en) | 2022-12-27 |
| US20190338285A1 (en) | 2019-11-07 |
| EP3452595A1 (en) | 2019-03-13 |
| SG11201809753YA (en) | 2018-12-28 |
| AU2022241489A1 (en) | 2022-10-20 |
| PH12018502320A1 (en) | 2022-01-24 |
| RU2018142797A (ru) | 2020-06-05 |
| CA3023185A1 (en) | 2017-11-09 |
| WO2017190197A1 (en) | 2017-11-09 |
| CN109415733A (zh) | 2019-03-01 |
| US20230093951A1 (en) | 2023-03-30 |
| KR20190003756A (ko) | 2019-01-09 |
| AU2017260580A1 (en) | 2018-11-22 |
| RU2018142797A3 (enExample) | 2020-09-10 |
| JP2019514401A (ja) | 2019-06-06 |
| AU2017260580B2 (en) | 2022-07-28 |
| RU2748806C2 (ru) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kang et al. | Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges | |
| JP2005521393A5 (enExample) | ||
| RU2013124422A (ru) | Лечение hbv-инфекции | |
| JP2016522674A5 (enExample) | ||
| JP2015518713A5 (enExample) | ||
| RU2020108189A (ru) | Композиции и способы лечения бокового амиотрофического склероза (als) | |
| JP2015518710A5 (enExample) | ||
| JP2015518712A5 (enExample) | ||
| RU2015133252A (ru) | Лечение возрастной макулярной дегенерации | |
| JP2015523855A5 (enExample) | ||
| JP2019508045A5 (enExample) | ||
| RU2018137677A (ru) | Модифицированная промоторная система u6 для тканеспецифической экспрессии | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| RU2021113126A (ru) | Средства для лечения инфекции вируса гепатита в (hbv) и их применение | |
| JP2020503014A5 (enExample) | ||
| JP2020527167A5 (enExample) | ||
| RU2019121950A (ru) | Реагенты для лечения окулофарингеальной мышечной дистрофии (офмд) и их применение | |
| CN114729354A (zh) | 炎性相关疾病防治的小rna药物及其组合 | |
| JP2019514401A5 (enExample) | ||
| JP2019513395A5 (enExample) | ||
| RU2018138271A (ru) | Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение | |
| Zhang et al. | Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1 | |
| TWI670064B (zh) | 抗病毒劑及治療病毒感染之方法 | |
| EA200500873A1 (ru) | Набор анти-вич- олигонуклеотидов и способ их применения для профилактики и лечения синдрома приобретенного иммунодефицита | |
| WO2018053019A1 (en) | Compositions and methods for treatment of enterovirus infection |